ABCSTRACT INSTRUCTIONS
Abstracts should be written in English and should be no longer than 500 words. The abstract title should be no longer than 50 words, and should clearly indicate the nature of the paper. The author’s affiliation should include the name of the organization and its country. The corresponding author should also include the contact e-mail address. The abstract must represent original work and should be as informative as possible. Conclusions must be supported by data.
The body of the abstract should be ordered as follows:
- Objectives
- Materials and Methods
- Results
- Conclusions
It is the author’s responsibility to submit a correct abstract. Any error in spelling, grammar or scientific fact will be reproduced as typed by the author. Once the abstract has been submitted, modified or deleted, the corresponding author will automatically receive an acknowledgement of receipt, modification or cancellation (by email). Abstracts cannot be withdrawn after the abstract submission deadline. The presenting author is responsible for giving the oral or
e-poster presentations if the abstract is accepted. Correspondence regarding the abstracts such as confirmation of submission, notification of acceptance or rejection and instructions for presentation will only be sent to the corresponding author. It is his/her responsibility to forward the information to all
co-authors. The presenting author is required to register for the Congress and pay the registration fee as a condition of presenting the paper.
Abstract Submission
Please, register as an active participant and submit your abstract by filling in the registration form or via e-mail to: kami@agenturakami.sk.
Final Close of abstracts: February 28, 2025.
Abstract example
Effects of subcutaneously injected Ca Cu EDTA on reproductive performance in New Zealand dairy cows
Hawkins, D.
Franklin Vets, Waiuku, New Zealand
Objectives: To determine the effect of a single 200 mg treatment administered 10 days prior to mating start date (MSD) on reproductive performance in New Zealand dairy cows.
Methods: In seven dairy herds from throughout New Zealand cows were stratified by age and calving date and then randomly assigned to either treatment or control groups. Treatment cows were injected S/C with 200 mg Cu 10 days prior to mating start date (MSD). Control cows received no treatment. Oestrus detection and artificial inseminations were carried out for ≥24 days from MSD. Pregnancy diagnosis was performed at 12 weeks following MSD. The percentage of cows inseminated in the 21 days after MSD (21-day submission rate; n=2,022) and cows pregnant after 21 or 28 days (21- and 28-day pregnancy rates; n=2520) was determined. This study was funded by International Animal Health Products LTD.
Results: Compared with Control cows, treating with 200 mg Cu 10 days before MSD reduced 21-day submission (78 vs. 75%; p=0.04) and 21-day pregnancy rates (47 vs. 43%; p=0.03). For 28-day pregnancy rates there was a farm by treatment interaction (p=0.02), with a negative effect observed on some, but not other, farms. The decrease in farm pregnancy rates were not always matched by proportional decreases in submission rates. Interval from calving and age were positively associated with submission and pregnancy rates.
Conclusions: Injection of 200 mg Ca Cu EDTA 10 days prior to mating had a negative effect on submission and pregnancy rates. The variability in submission rates compared to pregnancy rates suggests that more than one mechanism may be responsible for the observed effects. Further study is required to determine a safe treatment to mating interval and the mechanism by which adverse impacts occur. Although 200 mg of Cu as Ca Cu EDTA is an effective supplement, determining the necessity for, and the timing of, parenteral Cu supplementation is imperative to avoid negative impacts on herd reproductive performance.